Using Network Pharmacology to Explore Potential Treatment Mechanism for Coronary Heart Disease Using Chuanxiong and Jiangxiang Essential Oils in Jingzhi Guanxin Prescriptions

Table 1

Top 20 enriched KEGG pathways and top 10 enriched GO pathways.

Description	p value	p.adjust	q value	Count	Source
Retinol metabolism	2.77E – 06	8.12E – 05	3.51E – 05	4	KEGG
Metabolism of xenobiotics by cytochrome P450	4.60E – 06	8.12E – 05	3.51E – 05	4	KEGG
Chemical carcinogenesis	6.25E – 06	8.12E – 05	3.51E – 05	4	KEGG
Steroid hormone biosynthesis	9.79E – 05	9.54E – 04	4.12E – 04	3	KEGG
Adipocytokine signaling pathway	1.56E – 04	1.07E – 03	4.63E – 04	3	KEGG
Drug metabolism—cytochrome P450	1.77E – 04	1.07E – 03	4.63E – 04	3	KEGG
PPAR signaling pathway	1.93E – 04	1.07E – 03	4.63E – 04	3	KEGG
Th17 cell differentiation	5.72E – 04	2.79E – 03	1.20E – 03	3	KEGG
Ascorbate and aldarate metabolism	8.12E – 04	3.52E – 03	1.52E – 03	2	KEGG
Pentose and glucuronate interconversions	1.29E – 03	5.03E – 03	2.17E – 03	2	KEGG
Thyroid cancer	1.53E – 03	5.41E – 03	2.34E – 03	2	KEGG
Porphyrin and chlorophyll metabolism	1.97E – 03	6.39E – 03	2.76E – 03	2	KEGG
Non-small-cell lung cancer	4.79E – 03	1.44E – 02	6.21E – 03	2	KEGG
Bile secretion	5.53E – 03	1.54E – 02	6.65E – 03	2	KEGG
Drug metabolism—other enzymes	6.81E – 03	1.77E – 02	7.64E – 03	2	KEGG
Small cell lung cancer	9.33E – 03	2.27E – 02	9.82E – 03	2	KEGG
Parathyroid hormone synthesis, secretion, and action	1.20E – 02	2.75E – 02	1.19E – 02	2	KEGG
Thyroid hormone signaling pathway	1.43E – 02	3.09E – 02	1.33E – 02	2	KEGG
Nonalcoholic fatty liver disease (NAFLD)	2.29E – 02	4.25E – 02	1.83E – 02	2	KEGG
Hepatitis C	1.80E – 02	3.69E – 02	1.59E – 02	2	KEGG
Cellular response to xenobiotic stimulus	6.58E – 08	3.75E – 05	1.97E – 05	5	GO-BP
Flavonoid metabolic process	1.09E – 07	3.75E – 05	1.97E – 05	3	GO-BP
Retinoic acid metabolic process	4.82E – 07	8.37E – 05	4.41E – 05	3	GO-BP
Cellular response to steroid hormone stimulus	4.85E – 07	8.37E – 05	4.41E – 05	5	GO-BP
Response to xenobiotic stimulus	6.64E – 07	9.16E – 05	4.82E – 05	5	GO-BP
Xenobiotic metabolic process	9.64E – 07	1.11E – 04	5.83E – 05	4	GO-BP
Antibiotic metabolic process	1.74E – 06	1.71E – 04	9.00E – 05	4	GO-BP
Regulation of lipid metabolic process	2.62E – 06	2.26E – 04	1.19E – 04	5	GO-BP
Response to steroid hormone	3.62E – 06	2.78E – 04	1.46E – 04	5	GO-BP
Xenobiotic catabolic process	2.32E – 05	1.46E – 03	7.67E – 04	2	GO-BP
Transcription factor complex	1.21E – 03	2.37E – 02	1.45E – 02	3	GO-CC
Receptor complex	1.53E – 03	2.37E – 02	1.45E – 02	3	GO-CC
RNA polymerase II transcription factor complex	4.38E – 03	3.97E – 02	2.43E – 02	2	GO-CC
Nuclear transcription factor complex	6.15E – 03	3.97E – 02	2.43E – 02	2	GO-CC
Endoplasmic reticulum chaperone complex	6.40E – 03	3.97E – 02	2.43E – 02	1	GO-CC
Invadopodium	1.02E – 02	5.28E – 02	3.23E – 02	1	GO-CC
Lamellipodium membrane	1.40E – 02	5.90E – 02	3.61E – 02	1	GO-CC
Apical plasma membrane	1.52E – 02	5.90E – 02	3.61E – 02	2	GO-CC
Cell projection membrane	1.84E – 02	6.24E – 02	3.82E – 02	2	GO-CC
Cytochrome complex	2.10E – 02	6.24E – 02	3.82E – 02	1	GO-CC
Nuclear receptor activity	2.61E – 08	1.45E – 06	7.15E – 07	4	GO-MF
Transcription factor activity, direct ligand-regulated sequence-specific DNA binding	2.61E – 08	1.45E – 06	7.15E – 07	4	GO-MF
Monocarboxylic acid binding	6.41E – 08	2.37E – 06	1.17E – 06	4	GO-MF
Retinoic acid binding	1.98E – 07	5.50E – 06	2.71E – 06	3	GO-MF
Retinoid binding	1.44E – 06	2.92E – 05	1.44E – 05	3	GO-MF
Isoprenoid binding	1.58E – 06	2.92E – 05	1.44E – 05	3	GO-MF
Carboxylic acid binding	6.03E – 06	8.72E – 05	4.30E – 05	4	GO-MF
Organic acid binding	6.29E – 06	8.72E – 05	4.30E – 05	4	GO-MF
Steroid hormone receptor activity	7.77E – 06	9.59E – 05	4.73E – 05	3	GO-MF
Protein heterodimerization activity	1.24E – 05	1.37E – 04	6.76E – 05	5	GO-MF